NPM1 and acute myeloid leukemia: <i>In vivo</i>, combination therapy improved survival in both MV4;11 and OCI-AML3 cell line and primary patient-derived <i>KMT2A</i>-<i>r</i> and <i>NPM1</i>-m AML xenograft models in NSG mice, effective even at reduced drug doses.